Dulaglutide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dulaglutide: From Type 2 Diabetes to Opsismodysplasia
One-Sentence Summary
Dulaglutide is a once-weekly injectable GLP-1 receptor agonist, originally used to treat type 2 diabetes. The TxGNN model predicts it may be effective for Opsismodysplasia, a rare skeletal dysplasia, but 0 clinical trials and 0 publications currently support this direction. The prediction is model-only and is not supported by any biological rationale.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus (the source data lists no approved indication text; this is from general drug knowledge) |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 97.05% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 11 (all under BLA125469) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source data. Dulaglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion from pancreatic beta cells. Its efficacy in type 2 diabetes is established.
The prediction is not mechanistically well supported. Opsismodysplasia is a rare skeletal dysplasia linked to INPPL1, and GLP-1 receptor agonism has no established role in chondrocyte or bone-growth pathways. The high score most likely reflects proximity in the knowledge graph, not biology.
The other nine predicted indications share the same weakness:
- Stiff person syndrome (classic and focal), scores 97.05%: autoimmune GABAergic disease. The graph link probably comes from its co-occurrence with type 1 diabetes.
- Thiamine-responsive dysfunction syndrome, 96.81%: a link through glucose metabolism is conceivable, but it would not address the transporter defect.
- Localized lipodystrophies (drug-induced, centrifugal, pressure-induced, idiopathic), 94.99%–95.62%: probably artifacts of the association between injectable diabetes drugs and injection-site lipodystrophy. Dulaglutide is itself a subcutaneous injectable.
- Pancreatic agenesis, 95.55%: implausible, because the drug needs beta cells to act and they are absent in this condition.
- Autoimmune oophoritis, 69.57%: no established immunomodulatory role, and it has the lowest score of the set.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The 5 main entries below are among 11 total authorizations. All 11 fall under one biologics license (BLA125469). The source data gives no approved indication text.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| BLA125469 | Trulicity | Injection, solution | Eli Lilly and Company |
| BLA125469 | TRULICITY | Injection, solution | A-S Medication Solutions |
| BLA125469 | Trulicity | Injection, solution | A-S Medication Solutions |
| BLA125469 | Trulicity | Injection, solution | A-S Medication Solutions |
| BLA125469 | Trulicity | Injection, solution | A-S Medication Solutions |
The drug is available only as an injectable.
Safety Considerations
Please refer to the package insert for safety information. No drug-drug interaction records were found in the source data.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is model-only (L5): there are no clinical trials or publications, and no plausible mechanistic link between GLP-1 receptor agonism and opsismodysplasia. The high score most likely reflects knowledge-graph adjacency. The other nine predicted indications have the same weakness.
To proceed, the following is needed:
- Confirm the original indication and mechanism of action from DrugBank or the package insert
- Package insert warnings and contraindications, which are needed for safety screening
- Preclinical or mechanistic evidence linking GLP-1 receptor signaling to INPPL1-related skeletal biology
- Any registered trials or case reports; none exist at present
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.